MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG reports Financial Results and Business Update for Q3 2024
24 oct. 2024 01h30 HE | Medigene AG
Planegg/Martinsried, October 24, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG reports Financial Results and Business Update for Q1 2024
26 avr. 2024 03h00 HE | Medigene AG
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Reports Financial Results and Corporate Update for Q3 2023
26 oct. 2023 02h30 HE | Medigene AG
Focus on executing the strategic plan and delivering shareholder valueFirst MDG2011 pre-clinical data support potential in solid tumor therapyExpansion of patent portfolio and license agreement for...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG reports financial results and business update for Q1 2023
03 mai 2023 01h30 HE | Medigene AG
Focus on executing the strategic plan and delivering shareholder valueMDG1015 pre-clinical data underline potential in solid tumor therapy Subsequent to Q1, expansion of tools and technologies in our...